| Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ... Hemasphere 5 (2), e528, 2021 | 768 | 2021 |
| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 658 | 2015 |
| Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients A Vijenthira, IY Gong, TA Fox, S Booth, G Cook, B Fattizzo, F Martín-Moro, ... Blood, The Journal of the American Society of Hematology 136 (25), 2881-2892, 2020 | 646 | 2020 |
| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial GJ Morgan, FE Davies, WM Gregory, K Cocks, SE Bell, AJ Szubert, ... The Lancet 376 (9757), 1989-1999, 2010 | 634 | 2010 |
| Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study AC Rawstron, JA Child, RM de Tute, FE Davies, WM Gregory, SE Bell, ... Journal of clinical oncology 31 (20), 2540-2547, 2013 | 497 | 2013 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 470 | 2016 |
| The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis GJ Morgan, WM Gregory, FE Davies, SE Bell, AJ Szubert, JM Brown, ... Blood, The Journal of the American Society of Hematology 119 (1), 7-15, 2012 | 463 | 2012 |
| Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) OC Goodyear, M Dennis, NY Jilani, J Loke, S Siddique, G Ryan, ... Blood, The Journal of the American Society of Hematology 119 (14), 3361-3369, 2012 | 462 | 2012 |
| Guidelines for the diagnosis and management of multiple myeloma 2011. JM Bird, RG Owen, S D'Sa, JA Snowden, G Pratt, J Ashcroft, K Yong, ... British journal of haematology 154 (1), 2011 | 461 | 2011 |
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Oncology 20 (1), 57-73, 2019 | 366 | 2019 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, DB Begum, NM Dahir, ... Nature communications 6 (1), 6997, 2015 | 362 | 2015 |
| Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond CS Chim, SK Kumar, RZ Orlowski, G Cook, PG Richardson, MA Gertz, ... Leukemia 32 (2), 252-262, 2018 | 331 | 2018 |
| Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma E Morris, K Thomson, C Craddock, P Mahendra, D Milligan, G Cook, ... Blood 104 (13), 3865-3871, 2004 | 325 | 2004 |
| Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation DI Marks, A Pagliuca, CC Kibbler, A Glasmacher, CP Heussel, M Kantecki, ... British journal of haematology 155 (3), 318-327, 2011 | 282 | 2011 |
| Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in … S Tauro, C Craddock, K Peggs, G Begum, P Mahendra, G Cook, J Marsh, ... Journal of Clinical Oncology 23 (36), 9387-9393, 2005 | 273 | 2005 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 264 | 2020 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 261 | 2019 |
| Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation GJ Morgan, FE Davies, WM Gregory, NH Russell, SE Bell, AJ Szubert, ... Blood, The Journal of the American Society of Hematology 118 (5), 1231-1238, 2011 | 258 | 2011 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 251 | 2018 |
| Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ... Journal of clinical oncology 40 (29), 3406-3418, 2022 | 250 | 2022 |
